Advertisement

Maximum Standardized Uptake Value on Positron Emission Tomography is Associated With More Advanced Disease and High-risk Features in Lung Adenocarcinoma

      18F-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography (FDG-PET/CT) has been widely used for preoperative staging of lung adenocarcinomas. The aim of this study was to determine whether a high maximum standardized uptake value (SUVmax) could correlate with pathological characteristics in those patients. We retrospectively reviewed patients with clinical stage 0–IA lung adenocarcinoma who underwent preoperative 18F-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography followed by curative anatomical resection. To identify more advanced disease and high-risk features, representing visceral pleural involvement, pulmonary metastasis, lymph node involvement, and lymphovascular involvement in resected surgical specimens, univariate and multivariate logistic regression analyses were performed. The optimal cutoff point for the SUVmax was determined by receiver operating characteristic analysis. In 2 groups divided according to the cutoff point, the disease-free survivals were calculated and compared using the Kaplan-Meier method and the log-rank test. More advanced disease and high-risk features were identified in 55 (18.9%) of the 291 patients. SUVmax was significantly correlated with more advanced disease and high-risk features, as did the consolidation/tumor ratio on computed tomography. Only 2 (1.2%) of the 169 patients with a SUVmax <3.20 showed more advanced disease and high-risk features, compared with 43.4% of patients with a SUVmax ≥3.20. The disease-free survival was significantly higher in patients with a SUVmax <3.20 than in those with a SUVmax ≥3.20 (P = 0.002). A high SUVmax correlates with more advanced disease and high-risk features in patients with clinical stage 0–IA lung adenocarcinoma. The SUVmax should be considered when deciding treatment strategy in early-stage lung adenocarcinoma.

      Graphical Abstract

      Keywords

      Abbreviations:

      CEA (carcinoembryonic antigen), CI (confidence interval), Cons/Tumor ratio (consolidation/tumor ratio), CT (computed tomography), DFS (disease-free survival), FDG (18F-fluoro-2-deoxy-D-glucose), IQR (interquartile range), MRI (magnetic resonance imaging), NSCLC (non-small cell lung cancer), PET (positron emission tomography), ROC (receiver operating characteristic), SCC (squamous cell carcinoma antigen), SLX (sialyl Lewis-x antigen), SUVmax (maximum standardized uptake value)
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Seminars in Thoracic and Cardiovascular Surgery
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Bray F.
        • Ferlay J.
        • Soerjomataram I.
        • et al.
        Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.
        CA Cancer J Clin. 2018; 68: 394-424
        • Gregor A.
        • Inage T.
        • Hwangbo B.
        • et al.
        Lung cancer staging: State of the art in the era of ablative therapies and surgical segmentectomy.
        Respirology. 2020; 25: 924-932
        • Shim S.S.
        • Lee K.S.
        • Kim B.T.
        • et al.
        Non-small cell lung cancer: Prospective comparison of integrated FDG PET/CT and CT alone for preoperative staging.
        Radiology. 2005; 236: 1011-1019
        • Kandathil A.
        • Kay F.U.
        • Butt Y.M.
        • et al.
        Role of FDG PET/CT in the eighth edition of TNM staging of non-small cell lung cancer.
        Radiographics. 2018; 38: 2134-2149
        • Cerfolio R.J.
        • Bryant A.S.
        • Ohja B.
        • et al.
        The maximum standardized uptake values on positron emission tomography of a non-small cell lung cancer predict stage, recurrence, and survival.
        J Thorac Cardiovasc Surg. 2005; 130: 151-159
        • Al-Sarraf N.
        • Gately K.
        • Lucey J.
        • et al.
        Clinical implication and prognostic significance of standardised uptake value of primary non-small cell lung cancer on positron emission tomography: Analysis of 176 cases.
        Eur J Cardiothorac Surg. 2008; 34: 892-897
        • Okada M.
        • Nakayama H.
        • Okumura S.
        • et al.
        Multicenter analysis of high-resolution computed tomography and positron emission tomography/computed tomography findings to choose therapeutic strategies for clinical stage IA lung adenocarcinoma.
        J Thorac Cardiovasc Surg. 2011; 141: 1384-1391
        • Kwon W.
        • Howard B.A.
        • Herndon J.E.
        • et al.
        FDG uptake on positron emission tomography correlates with survival and time to recurrence in patients with stage I non-small-cell lung cancer.
        J Thorac Oncol. 2015; 10: 897-902
        • Brierley J.
        • Gospodarowicz M.K.
        • Wittekind C.
        TNM Classification of Malignant Tumours.
        Eighth edition. ed. John Wiley & Sons, Inc., Chichester, West Sussex, UK; Hoboken, NJ2017
        • Koike T.
        • Koike T.
        • Yamato Y.
        • et al.
        Prognostic predictors in non-small cell lung cancer patients undergoing intentional segmentectomy.
        Ann Thorac Surg. 2012; 93: 1788-1794
        • Koike T.
        • Koike T.
        • Yoshiya K.
        • et al.
        Risk factor analysis of locoregional recurrence after sublobar resection in patients with clinical stage IA non-small cell lung cancer.
        J Thorac Cardiovasc Surg. 2013; 146: 372-378
        • Koike T.
        • Nakamura A.
        • Shimizu Y.
        • et al.
        Characteristics and risk factors of recurrence in clinical stage I non-small cell lung cancer patients undergoing anatomic segmentectomy.
        Gen Thorac Cardiovasc Surg. 2020; 68: 1011-1017
        • Koike T.
        • Goto T.
        • Kitahara A.
        • et al.
        Characteristics and timing of recurrence during postoperative surveillance after curative resection for lung adenocarcinoma.
        Surg Today. 2017; 47: 1469-1475
        • Brinkman G.L.
        • Coates Jr., E.O.
        The effect of bronchitis, smoking, and occupation on ventilation.
        Am Rev Respir Dis. 1963; 87: 684-693
        • Suzuki K.
        • Koike T.
        • Asakawa T.
        • et al.
        A prospective radiological study of thin-section computed tomography to predict pathological noninvasiveness in peripheral clinical IA lung cancer (Japan Clinical Oncology Group 0201).
        J Thorac Oncol. 2011; 6: 751-756
        • Travis W.D.
        • Brambilla E.
        • Burke A.P.
        • et al.
        Introduction to the 2015 World Health Organization classification of tumors of the lung, pleura, thymus, and heart.
        J Thorac Oncol. 2015; 10: 1240-1242
        • Church T.R.
        • Black W.C.
        • National Lung Screening Trial Research T
        Results of initial low-dose computed tomographic screening for lung cancer.
        N Engl J Med. 2013; 368: 1980-1991
        • Ghaly G.
        • Rahouma M.
        • Kamel M.K.
        • et al.
        Clinical predictors of nodal metastases in peripherally clinical T1a N0 non-small cell lung cancer.
        Ann Thorac Surg. 2017; 104: 1153-1158
        • Resio B.J.
        • Canavan M.
        • Mase V.
        • et al.
        Invasive staging procedures do not prevent nodal metastases from being missed in stage I lung cancer.
        Ann Thorac Surg. 2020; 110: 390-397
        • Gerbaudo V.H.
        • Julius B.
        Anatomo-metabolic characteristics of atelectasis in F-18 FDG-PET/CT imaging.
        Eur J Radiol. 2007; 64: 401-405
        • Lv Y.L.
        • Yuan D.M.
        • Wang K.
        • et al.
        Diagnostic performance of integrated positron emission tomography/computed tomography for mediastinal lymph node staging in non-small cell lung cancer: A bivariate systematic review and meta-analysis.
        J Thorac Oncol. 2011; 6: 1350-1358
        • van Tinteren H.
        • Hoekstra O.S.
        • Smit E.F.
        • et al.
        Effectiveness of positron emission tomography in the preoperative assessment of patients with suspected non-small-cell lung cancer: the PLUS multicentre randomised trial.
        Lancet. 2002; 359: 1388-1393
        • Koike T.
        • Koike T.
        • Yamato Y.
        • et al.
        Predictive risk factors for mediastinal lymph node metastasis in clinical stage IA non-small-cell lung cancer patients.
        J Thorac Oncol. 2012; 7: 1246-1251
        • Umakoshi H.
        • Iwano S.
        • Yokoi K.
        • et al.
        FDG PET/CT overcomes discordance between clinical and pathologic TNM classification of small-size primary lung cancer: Influence on postoperative prognosis.
        Clin Lung Cancer. 2018; 19: e37-e45
        • Higashi K.
        • Ueda Y.
        • Yagishita M.
        • et al.
        FDG PET measurement of the proliferative potential of non-small cell lung cancer.
        J Nucl Med. 2000; 41: 85-92
        • Li M.
        • Sun Y.
        • Liu Y.
        • et al.
        Relationship between primary lesion FDG uptake and clinical stage at PET-CT for non-small cell lung cancer patients: An observation.
        Lung Cancer. 2010; 68: 394-397
        • Kagimoto A.
        • Tsutani Y.
        • Izaki Y.
        • et al.
        Prediction of lymph node metastasis using semiquantitative evaluation of PET for lung adenocarcinoma.
        Ann Thorac Surg. 2020; 110: 1036-1042
        • Verma S.
        • Chan J.
        • Chew C.
        • et al.
        PET-SUV max and upstaging of lung cancer.
        Heart Lung Circ. 2019; 28: 436-442
        • Ichikawa T.
        • Aokage K.
        • Miyoshi T.
        • et al.
        Correlation between maximum standardized uptake values on FDG-PET and microenvironmental factors in patients with clinical stage IA radiologic pure-solid lung adenocarcinoma.
        Lung Cancer. 2019; 136: 57-64
        • Satoh Y.
        • Onishi H.
        • Nambu A.
        • et al.
        Volume-based parameters measured by using FDG PET/CT in patients with stage I NSCLC treated with stereotactic body radiation therapy: Prognostic value.
        Radiology. 2014; 270: 275-281
        • Scagliotti G.V.
        • Pastorino U.
        • Vansteenkiste J.F.
        • et al.
        Randomized phase III study of surgery alone or surgery plus preoperative cisplatin and gemcitabine in stages IB to IIIA non-small-cell lung cancer.
        J Clin Oncol. 2012; 30: 172-178
        • Group N.M.-a.C.
        • Arriagada R.
        • Auperin A.
        • et al.
        Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: Two meta-analyses of individual patient data.
        Lancet. 2010; 375: 1267-1277
        • Boellaard R.
        • Oyen W.J.
        • Hoekstra C.J.
        • et al.
        The Netherlands protocol for standardisation and quantification of FDG whole body PET studies in multi-centre trials.
        Eur J Nucl Med Mol Imaging. 2008; 35: 2320-2333
        • Nakayama H.
        • Okumura S.
        • Daisaki H.
        • et al.
        Value of integrated positron emission tomography revised using a phantom study to evaluate malignancy grade of lung adenocarcinoma: A multicenter study.
        Cancer. 2010; 116: 3170-3177

      Linked Article

      • Commentary: Should Standard Uptake Value Decide Who Gets Surgery?
        Seminars in Thoracic and Cardiovascular SurgeryVol. 34Issue 3
        • Preview
          We read the article by Koike et al. regarding the role of positron emission tomography–computed tomography (PET-CT) in the management of lung cancer with great interest.1 Management of patients with early stage lung cancer remains a clinical challenge, as many patients are ultimately upstaged on pathologic analysis after surgery. Evolving our understanding of this disease is essential to our patients. We applaud the authors’ thorough review of current literature regarding the clinical use of the maximum standard uptake value (SUVmax).
        • Full-Text
        • PDF
      • Commentary: A Guiding Light in the Night?: Maximum Standardized Uptake Value Associated With High-Risk Features in Lung Adenocarcinoma
        Seminars in Thoracic and Cardiovascular SurgeryVol. 34Issue 3
        • Preview
          Positron emission tomography scans have become a key part of the staging work up for non-small cell lung carcinoma. In the current issue, Koike et al. performed a retrospective study of 297 patients who underwent resection for stage 0-IA lung adenocarcinoma and found that the maximum standardized uptake value (SUVmax) was associated with high-risk features including visceral pleural involvement, pulmonary metastasis, nodal disease, and lymphovascular invasion.1 While this is a potentially important finding since many patients, even those with early stage lung cancer, will develop recurrent disease, there are some weaknesses in the study design.
        • Full-Text
        • PDF